Trial Profile
A Phase II Trial of Reduced Intensity Allogeneic Stem Cell Transplantation With Fludarabine, Melphalan and Low Dose Total Body Irradiation
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Fludarabine (Primary) ; Melphalan (Primary) ; Methotrexate; Mycophenolate mofetil; Mycophenolate mofetil; Tacrolimus; Tacrolimus
- Indications Acute myeloid leukaemia; Aplastic anaemia; Bone marrow disorders; Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Diffuse large B cell lymphoma; Graft-versus-host disease; Haematological malignancies; Hodgkin's disease; Immunological disorders; Lymphoid leukaemia; Lymphoproliferative disorders; Multiple myeloma; Myelodysplastic syndromes; Myelofibrosis; Myeloproliferative disorders; Non-Hodgkin's lymphoma; Paroxysmal nocturnal haemoglobinuria; Precursor cell lymphoblastic leukaemia-lymphoma; Waldenstrom's macroglobulinaemia
- Focus Biomarker; Therapeutic Use
- 16 Sep 2019 Status changed from active, no longer recruiting to completed.
- 15 Mar 2019 Planned End Date changed from 1 Mar 2019 to 1 Aug 2019.
- 15 Jan 2019 Planned End Date changed from 1 Dec 2018 to 1 Mar 2019.